FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2466872787> ?p ?o ?g. }

• W2466872787 endingPage "134" @default.
• W2466872787 startingPage "133" @default.
• W2466872787 abstract "The PENTA Steering committee now recommends antiretroviral therapy (ART) for all children and adolescents living with HIV. Priority should be given to infants and children under 3 years of age, to adolescents, and to children with symptoms and/or low age-specific CD4 counts. The 2015 PENTA guideline recommended considering ART for all children diagnosed before their third birthday, with CD4 count guided thresholds for older children 1. Following the results of the START - Strategic Timing of AntiRetroviral Treatment study, World Health Organization (WHO), US and European guidelines now recommend treatment for all HIV-infected adults and adolescents irrespective of CD4 count. Such recommendations take into account the benefits of universal treatment in reducing onward transmission, including mother-to-child transmission. WHO paediatric guidelines recommend treatment for all children, with prioritization of children under 5 years old and those with symptoms or low CD4 counts. The Children with HIV Early Antiretroviral Therapy (CHER) study provided strong randomized controlled trial (RCT) evidence for early treatment of all infants. RCT evidence for the benefit of ART for children aged 1–10 years with good CD4 counts is lacking. Previous PENTA guidelines extended the recommendation for all children under 3 years because of the potential for rapid disease progression at higher CD4 counts 1. Universal treatment for all adolescents (WHO definition 10–19 years) can now be recommended based on extrapolation of adult START data and in prevention of onward transmission to partners as this population becomes sexually active. There is no equivalent to START data on short- to medium-term benefits of early ART in younger children, where there is no additional benefit of prevention of onward transmission. We recognize that, in the absence of RCT data, there are potential concerns about the earlier start of lifelong ART in children, with insufficient data on cumulative toxicity and concerns regarding adherence because of poor palatability and limited combination paediatric formulations. However, there is increasing evidence of the longer term benefits of early ART, including reduced mortality in low- and middle-income countries, improved neurodevelopmental, growth and pubertal outcomes, improved immune reconstitution and reduced inflammation and latent reservoir cohort data also demonstrate a reduced risk of virological failure when ART is started in childhood compared with adolescence 2-5. On this basis, we now also conclude that all children should be started on ART. For children with good CD4 counts, time can be taken to address adherence and psychosocial issues, but discussion on starting treatment should be initiated soon after the diagnosis, and children not on ART closely monitored. While concern about the additional cost of providing ART to all children in low- and middle-income settings may require individual countries to analyse the financial impact when changing national guidelines, in European cohorts more than 90% of diagnosed children are already on ART. The potential benefits of ART outweigh the potential problems for children of all ages living with HIV. The time is now right to recommend ART for all children with HIV infection. Jintanat Anworanich, Alasdair Bamford, Diane Bastiaans, Stefania Bernardi, Rosa Bologna, David Burger, Alexandra Compagnucci, Elena Chiappini, Polly Clayden, Marinella Della Negra, Katja Doerholt, Catherine Dolfus, Albert Faye, Caroline Foster, Vania Giacomet, Marc Hainaut, Nigel Klein, Mark Lallemant, Hermione Lyall, Laura Marques, Diane Melvin, Eleni Nastouli, Tim Niehues, Ton Noguera, Jolanta Popielska, Filipa Prata, Pablo Rojo, Henriette Scherpbier, Delane Shingadia, Gareth Tudor-Williams, Anna Turkova, Steve Welch." @default.
• W2466872787 created "2016-07-22" @default.
• W2466872787 creator A5005617480 @default.
• W2466872787 creator A5015306937 @default.
• W2466872787 creator A5026415916 @default.
• W2466872787 creator A5051328970 @default.
• W2466872787 creator A5069979058 @default.
• W2466872787 date "2016-07-06" @default.
• W2466872787 modified "2023-10-04" @default.
• W2466872787 title "Paediatric European Network for Treatment of AIDS Treatment Guideline 2016 update: antiretroviral therapy recommended for all children living with HIV" @default.
• W2466872787 cites W1517608807 @default.
• W2466872787 cites W2168039974 @default.
• W2466872787 cites W2330094743 @default.
• W2466872787 doi "https://doi.org/10.1111/hiv.12399" @default.
• W2466872787 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5248631" @default.
• W2466872787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27385585" @default.
• W2466872787 hasPublicationYear "2016" @default.
• W2466872787 type Work @default.
• W2466872787 sameAs 2466872787 @default.
• W2466872787 citedByCount "17" @default.
• W2466872787 countsByYear W24668727872017 @default.
• W2466872787 countsByYear W24668727872018 @default.
• W2466872787 countsByYear W24668727872019 @default.
• W2466872787 countsByYear W24668727872020 @default.
• W2466872787 countsByYear W24668727872021 @default.
• W2466872787 countsByYear W24668727872022 @default.
• W2466872787 countsByYear W24668727872023 @default.
• W2466872787 crossrefType "journal-article" @default.
• W2466872787 hasAuthorship W2466872787A5005617480 @default.
• W2466872787 hasAuthorship W2466872787A5015306937 @default.
• W2466872787 hasAuthorship W2466872787A5026415916 @default.
• W2466872787 hasAuthorship W2466872787A5051328970 @default.
• W2466872787 hasAuthorship W2466872787A5069979058 @default.
• W2466872787 hasBestOaLocation W24668727871 @default.
• W2466872787 hasConcept C119599485 @default.
• W2466872787 hasConcept C126322002 @default.
• W2466872787 hasConcept C127413603 @default.
• W2466872787 hasConcept C142462285 @default.
• W2466872787 hasConcept C142724271 @default.
• W2466872787 hasConcept C168563851 @default.
• W2466872787 hasConcept C187212893 @default.
• W2466872787 hasConcept C2780182762 @default.
• W2466872787 hasConcept C2908647359 @default.
• W2466872787 hasConcept C2993143319 @default.
• W2466872787 hasConcept C3013748606 @default.
• W2466872787 hasConcept C512399662 @default.
• W2466872787 hasConcept C71924100 @default.
• W2466872787 hasConcept C761482 @default.
• W2466872787 hasConcept C99454951 @default.
• W2466872787 hasConceptScore W2466872787C119599485 @default.
• W2466872787 hasConceptScore W2466872787C126322002 @default.
• W2466872787 hasConceptScore W2466872787C127413603 @default.
• W2466872787 hasConceptScore W2466872787C142462285 @default.
• W2466872787 hasConceptScore W2466872787C142724271 @default.
• W2466872787 hasConceptScore W2466872787C168563851 @default.
• W2466872787 hasConceptScore W2466872787C187212893 @default.
• W2466872787 hasConceptScore W2466872787C2780182762 @default.
• W2466872787 hasConceptScore W2466872787C2908647359 @default.
• W2466872787 hasConceptScore W2466872787C2993143319 @default.
• W2466872787 hasConceptScore W2466872787C3013748606 @default.
• W2466872787 hasConceptScore W2466872787C512399662 @default.
• W2466872787 hasConceptScore W2466872787C71924100 @default.
• W2466872787 hasConceptScore W2466872787C761482 @default.
• W2466872787 hasConceptScore W2466872787C99454951 @default.
• W2466872787 hasIssue "2" @default.
• W2466872787 hasLocation W24668727871 @default.
• W2466872787 hasLocation W24668727872 @default.
• W2466872787 hasLocation W24668727873 @default.
• W2466872787 hasLocation W24668727874 @default.
• W2466872787 hasLocation W24668727875 @default.
• W2466872787 hasLocation W24668727876 @default.
• W2466872787 hasLocation W24668727877 @default.
• W2466872787 hasOpenAccess W2466872787 @default.
• W2466872787 hasPrimaryLocation W24668727871 @default.
• W2466872787 hasRelatedWork W1973460911 @default.
• W2466872787 hasRelatedWork W2096903645 @default.
• W2466872787 hasRelatedWork W2911784407 @default.
• W2466872787 hasRelatedWork W3159250744 @default.
• W2466872787 hasRelatedWork W4249487090 @default.
• W2466872787 hasRelatedWork W4256514411 @default.
• W2466872787 hasRelatedWork W4292236216 @default.
• W2466872787 hasRelatedWork W148066406 @default.
• W2466872787 hasRelatedWork W2083697902 @default.
• W2466872787 hasRelatedWork W2522518582 @default.
• W2466872787 hasVolume "18" @default.
• W2466872787 isParatext "false" @default.
• W2466872787 isRetracted "false" @default.
• W2466872787 magId "2466872787" @default.
• W2466872787 workType "article" @default.